Daily non-political popular news in brief.

Drug helps brain tumor patients live longer

People who receive high doses of the chemotherapy drug methotrexate to treat a certain type of brain tumor appear to live longer than people receiving other treatments, according to research published in the Jan. 29, 2008, issue of Neurology, the medical journal of the American Academy of Neurology.

Read more »

Keywords: drug, brain, tumor, patients, live, longer, patient

« Previous | Next »

Similar news on "Drug helps brain tumor patients live longer":

1. Drug combination might offer hope for patients deadly brain tumors
   10-18-2007 · EurekAlert!
   Brain cancer patients with the poorest prognosis -- those with a type of deadly tumor known as glioblastoma multiforme -- may survive longer with a drug that chokes off a tumor's blood supply.
   Similar news · Read more »
   
2. Treatment capitalizes on unique qualities of radioisotope to prolong lives of brain tumor patients
   01-30-2008 · EurekAlert!
   In a study to determine safe dosages of the isotope astatine-211 for patients with recurring brain tumors, researchers were pleasantly surprised to find that not only was the isotope's potency sufficient to kill residual cancer cells without damaging sensitive healthy brain cells, but the patients experienced longer survival rates.
   Similar news · Read more »
   
3. Cetuximab may prolong survival for head and neck cancer patients
   01-18-2007 · EurekAlert!
   Preliminary findings show adding the chemotherapy drug cetuximab (brand name Erbitux) to radiation therapy and chemotherapy may help some patients with head and neck cancer live longer, according to a study presented at the plenary session of the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.
   Similar news · Read more »
   
4. Molecules may help predict survival in liver cancer
   01-30-2008 · EurekAlert!
   Tiny molecules that help cells regulate which proteins they make might one day help doctors predict which liver-cancer patients are likely to live longer than others. Researchers compared levels of microRNA in tumor cells and adjacent nontumor cells from liver-cancer patients, most of whom also had hepatitis and cirrhosis. Patients with poor disease-free survival had low overall levels of 19 particular microRNAs compared with those showing better survival after 16 years of follow-up.
   Similar news · Read more »
   
5. New tumor markers -- 'Spot the differences'
   06-20-2007 · EurekAlert!
   Pancreatic cancer, the subject of this thesis, has the poorest prognosis of all cancers: the survival rate after 5 years with the disease is less than 5 percent and on average, patients who have been diagnosed with it do not live longer than 6 months.
   Similar news · Read more »
   
6. Research suggests new treatment suitable for all patients
   01-01-2008 · EurekAlert!
   New research at Wake Forest University Baptist Medical Center suggests that a three-drug cocktail may one day improve outcomes in patients with glioblastoma multiforme, a type of brain tumor with a dismal prognosis. Two of the drug candidates have been developed, and the team is working on the third -- all targeted to kill or impair cancer cells and spare healthy brain.
   Similar news · Read more »
   
7. Mayo Clinic Cancer Center -- individualizing treatment for multiple myeloma patients
   12-10-2006 · EurekAlert!
   Researchers at Mayo Clinic Cancer Center, in cooperation with industry partners, have, for the first time, identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works, and they have identified nine new genetic mutations in cancer cells that should increase a patient's chance of responding to the agent.
   Similar news · Read more »
   
8. New angiogenesis inhibitor has promise for treating deadly brain tumor
   01-16-2007 · EurekAlert!
   Researchers from the Massachusetts General Hospital Cancer Center have found that AZD2171, a new angiogenesis inhibitor, can significantly reduce the size of the deadly brain tumors called glioblastomas and has the potential of improving the effectiveness of other therapeutic techniques. The Phase 2 clinical trial also finds that the new drug can alleviate brain swelling (edema), a debilitating symptom in many brain cancer patients that currently can be treated only with steroid drugs.
   Similar news · Read more »
   
9. Pre-treatment blood test could guide lung cancer therapy
   06-05-2007 · EurekAlert!
   A multi-center team, led by Vanderbilt-Ingram Cancer Center investigators, has developed a new pre-treatment blood test that predicts which non-small-cell lung cancer patients will live longer when they are treated with certain targeted cancer therapies (Iressa, Tarceva). The mass spectrometry-based test, described in the June 6 Journal of the National Cancer Institute, may allow physicians to select the most beneficial therapy for each lung cancer patient, a step forward in the era of personalized medicine.
   Similar news · Read more »
   
10. Radiation plus chemo quadruples survival time for fatal brain cancer
    10-29-2007 · EurekAlert!
    Over four times as many patients with a rapidly fatal type of brain cancer, glioblastoma multiforme, who are treated with the chemotherapy drug temozolomide and radiation therapy, can live for four years after diagnosis, compared to those who receive only radiation treatment, according to updated results of a large, international trial presented at the Plenary I session on Oct. 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
    Similar news · Read more »